Organon & Co. OGN

Set alert

Price alert · OGN

All alert types
13.82 USD -0.02 -0.14%

At close · Nov 2

13.81 -0.01 -0.07%

After hours · Nov 2, 4:00 PM ET

Bid
13.81 × 10,600
Ask
13.83 × 15,500
13.82 Day range 13.84
5.69 52-week range 13.84
YTD
+92.75%
1 year
+104.74%
Open
13.85
Prev close
13.84
Mkt cap
3.63B
Vol
2.15M
Avg vol
2.58M
EPS
0.78
P/E
17.72
Div yield
0.58%
More statistics
Low
13.82
High
13.84
Forward P/E
3.79
Beta
1.49
Short ratio
8.54
Inst. own
84.58%
Dividend
0.08
Ex-div date
Nov 8, 2026
Earnings
Feb 11, 2027
50-d avg
13.74
200-d avg
11.52
1y target
10.33

2Y chart

Chart tools
Interval

Events in this range
  • Nov 12, 2024Dividend: 0.28
  • Feb 24, 2025Dividend: 0.28
  • May 12, 2025Dividend: 0.02
  • Aug 15, 2025Dividend: 0.02
  • Nov 10, 2025Earnings: 1.01; estimate 0.93; surprise 8.6%
  • Nov 11, 2025Rating: Morgan Stanley · Equal-Weight → Equal-Weight
  • Nov 11, 2025Rating: JP Morgan · Underweight → Underweight
  • Nov 20, 2025Dividend: 0.02
  • Dec 9, 2025Rating: Barclays · — → Underweight
  • Feb 12, 2026Earnings: 0.63; estimate 0.73; surprise -13.7%
  • Feb 23, 2026Dividend: 0.02
  • Feb 24, 2026Rating: Barclays · Underweight → Underweight
  • Apr 28, 2026Rating: Piper Sandler · Underweight → Neutral
  • Apr 29, 2026Downgrade: BNP Paribas · Outperform → Neutral
  • Apr 30, 2026Earnings: 0.71; estimate 0.83; surprise -14.46%
  • May 11, 2026Dividend: 0.02
  • Jul 31, 2026Earnings: 0.85; estimate 0.85; surprise 0%
  • Aug 14, 2026Dividend: 0.02
  • Oct 30, 2026Earnings: 0.94; estimate 0.88; surprise 6.82%
Signals (84)
NameDateAgo
MACD: Buy SignalOct 29, 20264 days ago
MACD: Sell SignalOct 19, 20262 weeks ago
MACD: Buy SignalOct 7, 20263 weeks ago
MACD: Sell SignalSep 30, 20261 month ago
MACD: Buy SignalSep 28, 20261 month ago
MACD: Sell SignalAug 28, 20262 months ago
RSI: OverboughtAug 19, 20262 months ago
MACD: Buy SignalAug 12, 20262 months ago
RSI: OverboughtAug 11, 20262 months ago
RSI: OverboughtJun 23, 20264 months ago
MACD: Sell SignalMay 12, 20265 months ago
RSI: OverboughtApr 24, 20266 months ago
SMA: BullishApr 10, 20266 months ago
SMA: BullishApr 10, 20266 months ago
RSI: OverboughtApr 10, 20266 months ago
MACD: Buy SignalMar 31, 20267 months ago
MACD: Sell SignalMar 30, 20267 months ago
RSI: OversoldMar 26, 20267 months ago
MACD: Buy SignalMar 25, 20267 months ago
RSI: OversoldMar 20, 20267 months ago

Newest 20 of 84.

Key statistics

Market cap
3.63B
Enterprise value
10.73B
Trailing P/E
17.72
Forward P/E
3.79
PEG ratio
0.00
Price / sales
0.60
Price / book
3.04
EPS (TTM)
0.78
Beta
1.49
Dividend yield
0.58%
Payout ratio
10.26%
Profit margin
3.49%
Revenue (TTM)
6.10B
Revenue growth
-1.70%
Free cash flow
721.37M
Total cash
1.46B
Total debt
8.55B
Return on equity
20.29%
Shares outstanding
262.62M
Short % of float
8.14%
50-day average
13.74
200-day average
11.52

Financials — quick view

All financials
OGN Revenue — quarterly 1.57B
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
OGN Net income — quarterly 164.00M
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
OGN EPS — quarterly 0.62
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026

Earnings

OGN recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 11, 2027Dec 30, 20260.92———
Oct 30, 2026Sep 30, 20260.880.94+0.06+6.82%
Jul 31, 2026Jun 30, 20260.850.850.000.00%
Apr 30, 2026Mar 31, 20260.830.71-0.12-14.46%
Feb 12, 2026Dec 31, 20250.730.63-0.10-13.70%
Nov 10, 2025Sep 30, 20250.931.01+0.08+8.60%

Upgrades / downgrades

OGN analyst upgrades and downgrades
DateFirmActionFromTo
Apr 29, 2026BNP ParibasdownOutperformNeutral
Apr 28, 2026Piper SandlerupUnderweightNeutral
Feb 24, 2026BarclaysmainUnderweightUnderweight
Dec 9, 2025Barclaysinit—Underweight
Nov 11, 2025JP MorganmainUnderweightUnderweight
Nov 11, 2025Morgan StanleymainEqual-WeightEqual-Weight

About Organon & Co.

Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote development of ovarian follicles; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products to control and prevent asthma symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.

Sector
Healthcare
Industry
Drug Manufacturers - General
Country
United States
Website
organon.com

News

Your note

Sign in to keep a note on OGN — it syncs with the Stock Master app.

Insider holders

OGN insider holders
InsiderRelationLatest transactionDateShares held
ALI KEVINChief Executive OfficerPurchaseMay 4, 2025282,731
COX CARRIE SMITHOfficer and DirectorPurchaseNov 11, 20250
FALCIONE AARONOfficerConversion of Exercise of derivative securityMar 30, 2026101,431
HOLZBAUR LYNETTEOfficerPurchaseMay 5, 202652,850
KARP DANIELOfficerConversion of Exercise of derivative securityMar 30, 202669,547
MORRISSEY JOSEPH T JRChief Executive OfficerConversion of Exercise of derivative securityMar 30, 2026123,123

Institution ownership

OGN institution ownership
Holder% heldSharesValueReported
Blackrock Inc.12.21%32,056,866443.19MJun 29, 2026
Pentwater Capital Management Lp6.89%18,100,000250.23MJun 29, 2026
Vanguard Portfolio Management LLC5.76%15,132,118209.20MJun 29, 2026
Vanguard Capital Management LLC4.54%11,909,865164.65MJun 29, 2026
State Street Corporation3.68%9,659,371133.54MJun 29, 2026
Goldman Sachs Group Inc1.98%5,199,00271.88MJun 29, 2026

Fund ownership

OGN fund ownership
Holder% heldSharesValueReported
iShares Trust-iShares Core S&P Small-Cap ETF5.95%15,638,261216.20MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.17%8,332,789115.20MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund2.29%6,024,69983.29MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Value Index Fund1.45%3,815,00152.74MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund1.15%3,010,25541.62MJun 29, 2026
NexPoint Funds I-NexPoint Merger Arbitrage Fund1.03%2,705,08037.40MJun 29, 2026